COMMUNIQUÉS West-GlobeNewswire

SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024

07/11/2024 - 22:05

Product Revenues for the Three and Nine months Ended September 30, 2024 were $9 million and $53 million, respectively Received $122 Million of Procurement Orders from the U.S. Government in the Third Quarter Corporate [...]

Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance

07/11/2024 - 22:05

MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, [...]

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

07/11/2024 - 22:05

Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/ [...]

PacBio Announces Third Quarter 2024 Financial Results

07/11/2024 - 22:05

MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: Revenue of $40.0 million compared with $55.7 [...]

Kura Oncology Reports Third Quarter 2024 Financial Results

07/11/2024 - 22:05

– Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a dose-escalation [...]

Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

07/11/2024 - 22:05

Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), advancing in two late-stage, registrational clinical trials in two indications Phase 3 sunRIZE study on track; U.S. [...]

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

07/11/2024 - 22:05

CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare [...]

RxSight, Inc. Reports Third Quarter 2024 Financial Results

07/11/2024 - 22:05

ALISO VIEJO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]

ProPhase Labs Announces Proposed Public Offering of Common Stock

07/11/2024 - 22:05

GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next-generation biotech, genomics and diagnostics company, today announced that it intends to offer to sell shares of its common [...]

The Joint Corp. Reports Third Quarter 2024 Financial Results

07/11/2024 - 22:05

SCOTTSDALE, Ariz., Nov. 07, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter ended September [...]

Senseonics Holdings, Inc. Reports Third Quarter 2024 Financial Results

07/11/2024 - 22:05

GERMANTOWN, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]

TELA Bio Reports Third Quarter 2024 Financial Results

07/11/2024 - 22:05

Reiterates 2024 Revenue Guidance and Expects Recently Implemented Operational Efficiency Improvements to Reduce Operating Expenses in 2025 MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a [...]

Profound Medical Announces Third Quarter 2024 Financial Results

07/11/2024 - 22:05

TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free [...]

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

07/11/2024 - 22:05

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: [...]

LifeMD Reports Third Quarter 2024 Results

07/11/2024 - 22:05

Total revenues increased 38% year-over-year to $53.4 million with telehealth revenue up 65% Record gross margin of 90.6%, up 300 basis points from the year-ago period Adjusted EBITDA increased 33% to $3.7 million [...]

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

07/11/2024 - 22:05

Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical [...]

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

07/11/2024 - 22:05

Highlights Third quarter revenue grew 11% year-over-year to $213 million , driven by Pharmacogenomics ( 34% ) and Prenatal ( 10% ) and progress on payor coverage and revenue cycle initiatives. Third quarter GAAP net [...]

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

07/11/2024 - 22:05

Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4’24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases’ (AASLD’s [...]

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting

07/11/2024 - 22:05

Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens Correlation observed between disease-free survival (“DFS”) and T [...]